A Phase 2, Placebo-controlled, Randomized, Observer-blinded Study To Evaluate The Safety, Tolerability, And Immunogenicity Of Two 3-dose Regimens Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 To 85 Years

Trial Profile

A Phase 2, Placebo-controlled, Randomized, Observer-blinded Study To Evaluate The Safety, Tolerability, And Immunogenicity Of Two 3-dose Regimens Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 To 85 Years

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs PF 6425090 (Primary)
  • Indications Clostridium infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 09 Mar 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2020.
    • 26 Jan 2017 Positive top-line results, based on a pre-planned interim analysis were announced, as per a Pfizer media release.
    • 19 Oct 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top